Válts MeRSZ+ -ra!

MeRSZ online
okoskönyvtár

Több száz tankönyv egy helyen.
Online. Bárhol. Bármikor.

Fazekas Tamás, Merkely Béla, Papp Gyula, Tenczer József (szerk.)

Klinikai szív-elektrofiziológia és aritmológia

Irodalom

  1. Aichter, S., Duray, G., Grönefeld, G., W. Israel, C. H., Hohnloser, S.: Prevention of sudden cardiac death: lessons from recent controlled trials. Circ. J., 2005, 69: 625–629.
  2. Echt, D. S., Liebson, P.R., Mitchell, L. B., Peters, R. W., Obias-Manno, D., Barker, A. H., Arensberg, D., Baker, A., Friedman, L., Greene, H. L. et al.: Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N. Engl. J. Med., 1991, 324: 781–788.
  3. Merkely, B., Roka, A., Geller, L.: Electrophysiologic practice in Hungary. Heart Rhythm., 2007, 4: 1123.
  4. Schaldach, M., Thong, T., Revishvili, A., Merkely, B., Lucchese, F.: Technology and algorithms for implantable dual chamber defibrillators. Biomed. Tech. (Berl), 1996, 41: 351–358.
  5. Kaup, H. J., Hexamer, M., Werner, J.: Morphological detection algorithms for the automatic implantable cardioverter/defibrillator (AICD). Biomed. Tech. (Berl), 2004, 49: 306–310.
  6. Alt, E., Evans, F., Wolf, P. D., Pasquantonio, J., Stotts, L., Heinz, S., Schömig, A.: Does reducing capacitance have potential for further miniaturisation of implantable defibrillators? Heart, 1997, 77: 234–237.
  7. Zima, E., Gergely, M., Soós, P., Gellér, L. A., Nemes, A., Acsády, G., Merkely, B.: The effect of induction method on defibrillation threshold and ventricular fibrillation cycle length. J. Cardiovasc. Electrophysiol., 2006, 17: 377–381.
  8. Kroll, M. W., Efimov, I. R., Tchou, P. J.: Present understanding of shock polarity for internal defibrillation: the obvious and non-obvious clinical implications. Pacing Clin. Electrophysiol., 2006, 29: 885–891.
  9. Merkely, B., Zima, E., Gellér, L., Lang, V., Schaldach, M.: A new detection algorithm for implantable cardioverter defibrillator. Biomed. Tech. (Berl), 2001, 46: 226–229.
  10. Theuns, D., Klootwijk, A. P., Kimman, G. P., Szili-Török, T., Roelandt, J. R., Jordaens, L.: Initial clinical experience with a new arrhythmia detection algorithm in dual chamber implantable cardioverter defibrillators Europace, 2001, 3: 181–186.
  11. Friedman, P. A., McClelland, R. L., Bamlet, W. R., Acosta, H., Kessler, D., Munger, T. M., Kavesh, N. G., Wood, M., Daoud, E., Massumi, A., Schuger, C., Shorofsky, S., Wilkoff, B., Glikson, M.: Dual-chamber versus single-chamber detection enhancements for implantable defibrillator rhythm diagnosis: the detect supraventricular tachycardia study. Circulation, 2006, 113: 2871–2879.
  12. Berger, R. D., Lerew, D. R., Smith, J. M., Pulling, C., Gold, M. R.: The Rhythm ID Going Head to Head Trial (RIGHT): design of a randomized trial comparing competitive rhythm discrimination algorithms in implantable cardioverter defibrillators. J. Cardiovasc. Electrophysiol., 2006, 17: 749–753.
  13. Dorian, P., Philippon, F., Thibault, B., Kimber, S., Sterns, L., Greene, M., Newman, D., Gelaznikas, R., Barr, A.: Randomized controlled study of detection enhancements versus rate-only detection to prevent inappropriate therapy in a dual-chamber implantable cardioverter-defibrillator. Heart Rhythm., 2004, 1: 540–547.
  14. Aliot, E., Nitzsché, R., Ripart, A.: Arrhythmia detection by dual-chamber implantable cardioverter defibrillators. A review of current algorithms. Europace, 2004, 6: 273–286.
  15. Peters, R. W., Zhang, X., Gold, M. R.: Clinical predictors and efficacy of antitachycardia pacing in patients with implantable cardioverter defibrillators: the importance of the patient’s sex. Pacing Clin. Electrophysiol., 2001, 24: 70–74.
  16. Wathen, M. S., DeGroot, P. J., Sweeney, M. O., Stark, A. J., Otterness, M. F., Adkisson, W. O., Canby, R. C., Khalighi, K., Machado, C., Rubenstein, D. S., Volosin, K. J.: Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators: Pacing Fast Ventricular Tachycardia Reduces Shock Therapies (PainFREE Rx II) trial results. Circulation, 2004, 110: 2591–2596.
  17. Wilkoff, B. L., Ousdigian, K. T., Sterns, L. D., Wang, Z. J., Wilson, R. D., Morgan, J. M.: A comparison of empiric to physician-tailored programming of implantable cardioverter-defibrillators: results from the prospective randomized multicenter EMPIRIC trial J. Am. Coll. Cardiol., 2006, 48: 330–339.
  18. Wilkoff, B. L., Williamson, B. D., Stern, R. S., Moore, S. L., Lu, F., Lee, S. W., Birgersdotter-Green, U. M., Wathen, M. S., Van Gelder, I. C., Heubner, B. M., Brown, M. L., Holloman, K. K.: Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study. J. Am. Coll. Cardiol., 2008, 52: 541–550.
  19. Grönefeld, G. C., Israel, C. W., Padmanabhan, V., Koehler, J., Cuijpers, A., Hohnloser, S. H.: Ventricular rate stabilization for the prevention of pause dependent ventricular tachyarrhythmias: results from a prospective study in 309 ICD recipients Pacing Clin. Electrophysiol., 2002, 25: 1708–1714.
  20. Viskin, S.: Cardiac pacing in the long QT syndrome: review of available data and practical recommendations. J. Cardiovasc. Electrophysiol., 2000, 11: 593–600.
  21. Neglia, J. J., Krol, R. B., Giorgberidze, I., Mathew, P., Lewis, C., Munsif, A. N., Saksena S.: Evaluation of a programming algorithm for the third tachycardia zone in a fourth-generation implantable cardioverter-defibrillator. J. Interv. Card. Electrophysiol., 1997, 1: 49–56.
  22. Swartz, J. F., Fletcher, R. D., Karasik, P. E.: Optimization of biphasic waveforms for human nonthoracotomy defibrillation. Circulation, 1997, 88: 2646–2654.
  23. Csanadi, Z., Jones, D. L., Wood, G. K., Klein, G. J.: Comparison of single-biphasic versus sequential-biphasic shocks on defibrillation threshold in pigs. Pacing Clin. Electrophysiol., 1997, 20: 1606–1612.
  24. Merkely, B., Lubiñski, A., Kiss, O., Horkay, F., Lewicka-Nowak, E., Kempa, M., Szabolcs, Z., Nyikos, G., Zima, E., Swiatecka, G., Gellér, L.: Shortening the second phase duration of biphasic shocks: effects of class III antiarrhythmic drugs on defibrillation efficacy in humans. J. Cardiovasc. Electrophysiol., 2001, 12: 824–827.
  25. Manoharan, G., Evans, N., Allen, D., Anderson, J., Adgey, J.: Comparing the efficacy and safety of a novel monophasic waveform delivered by the passive implantable atrial defibrillator with biphasic waveforms in cardioversion of atrial fibrillation. Circulation, 2004, 109: 1686–1692.
  26. Jayam, V., Zviman, M., Jayanti, V., Roguin, A., Halperin, H., Berger, R. D.: Internal defibrillation with minimal skeletal muscle activation: a new paradigm toward painless defibrillation. Heart Rhythm., 2005, 2: 1108–1113.
  27. Giudici, M. C., Barold, S. S., Paul, D. L., Schrumpf, P. E., Van Why, K. J., Orias, D. W.: Right ventricular outflow tract placement of defibrillation leads: five year experience. Pacing Clin. Electrophysiol., 2004, 27: 443–446.
  28. Epstein, A. E., Kay, G. N., Plumb, V. J., Voshage-Stahl, L., Hull, M. L.: Elevated defibrillation threshold when right-sided venous access is used for nonthoracotomy implantable defibrillator lead implantation. The Endotak Investigators. J. Cardiovasc. Electrophysiol., 1995, 6: 979–986.
  29. Swerdlow, C. D., Peter, C. T., Kass, R. M., Gang, E. S., Mandel, W. J., Hwang, C., Martin, D. J., Chen, P. S.: Programming of implantable cardioverter-defibrillators on the basis of the upper limit of vulnerability. Circulation, 1997, 95: 1497–1504.
  30. Green, U. B., Garg, A., Al-Kandari, F., Ungab, G., Tone, L., Feld, G. K.: Successful implantation of cardiac defibrillators without induction of ventricular fibrillation using upper limit of vulnerability testing. J. Interv. Card. Electrophysiol., 2003, 8: 71–75.
  31. Kettering, K., Mewis, C., Dörnberger, V., Vonthein, R., Bosch, R. F., Seipel, L., Kühlkamp, V.: Long-term experience with subcutaneous ICD leads: a comparison among three different types of subcutaneous leads. Pacing Clin. Electrophysiol., 2004, 27: 1355–1361.
  32. Cesario, D., Bhargava, M., Valderrábano, M., Fonarow, G. C., Wilkoff, B., Shivkumar, K.: Azygos vein lead implantation: a novel adjunctive technique for implantable cardioverter defibrillator placement. J. Cardiovasc. Electrophysiol., 2004, 15: 780–783.
  33. Hreybe, H., Razak, E., Saba, S.: Effect of end-stage renal failure and hemodialysis on mortality rates in implantable cardioverter-defibrillator recipients. Pacing Clin. Electrophysiol., 2007, 30: 1091–1095.
  34. Connolly, S. J., Hallstrom, A. P., Cappato, R., Schron, E. B., Kuck, K. H., Zipes, D.P., Greene, H. L., Boczor, S., Domanski, M., Follmann, D., Gent, M., Roberts, R. S.: Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur. Heart J., 2000, 21: 2071–2078.
  35. Lau, E. W., Griffith, M. J., Pathmanathan, R. K., Ng, G. A., Clune, M. M., Cooper, J., Marshall, H. J., Forsey, P. R., Stafford, P. J., Gray, R. G., Skehan, J. D., Garratt, C. J.: The Midlands Trial of Empirical Amiodarone versus Electrophysiology-guided Interventions and Implantable Cardioverter-defibrillators (MAVERIC): a multi-centre prospective randomised clinical trial on the secondary prevention of sudden cardiac death. Europace, 2004, 6: 257–266.
  36. Moss, A. J., Zareba, W., Hall, W. J., Klein, H., Wilber, D. J., Cannom, D. S., Daubert, J. P., Higgins, S. L., Brown, M. W., Andrews, M. L.: Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N. Engl. J. Med., 2002, 346: 877–883.
  37. Buxton, A. E., Lee, K. L., Fisher, J. D., Josephson, M. E., Prystowsky, E. N., Hafley, G.: A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N. Engl. J. Med., 1999, 341: 1882–1890.
  38. The CABG Patch Trial Investigators and Coordinators. The Coronary Artery Bypass Graft (CABG) Patch Trial Prog Cardiovasc Dis, 1993, 36(2): 97–114.
  39. Hohnloser, S. H., Kuck, K. H., Dorian, P., Roberts, R. S., Hampton, J. R., Hatala, R., Fain, E., Gent, M., Connolly, S. J.: Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N. Engl. J. Med., 2004, 351: 2481–2488.
  40. Raviele, A., Bongiorni, M. G., Brignole, M., Cappato, R., Capucci, A., Gaita, F., Gulizia, M., Mangiameli, S., Montenero, A. S., Pedretti, R. F. E., Uriarte, J. A. S., Sermasi, S., Nisam, S.: Early EPS/ICD strategy in survivors of acute myocardial infarction with severe left ventricular dysfunction on optimal beta-blocker treatment. The BEta-blocker STrategy plus ICD trial. Europace, 2005, 7: 327–337.
  41. Bänsch, D., Antz, M., Boczor, S., Volkmer, M., Tebbenjohanns, J., Seidl, K., Block, M., Gietzen, F., Berger, J., Kuck, K. H.: Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation, 2002, 105: 1453–1458.
  42. Wijetunga, M., Strickberger, S. A.: Amiodarone versus Implantable Defibrillator (AMIOVIRT): background, rationale, design, methods, results and implications. Card. Electrophysiol. Rev., 2003, 7: 452–456.
  43. Kadish, A., Dyer, A., Daubert, J. P., Quigg, R., Estes, N. A. M., Anderson, K. P., Calkins, H., Hoch, D., Goldberger, J., Shalaby, A., Sanders, W. E., Schaechter, A., Levine, J. H.: Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N. Engl. J. Med., 2004, 350: 2151–2158.
  44. Bardy, G. H., Lee, K. L., Mark, D. B., Poole, J. E., Packer, D. L., Boineau, R., Domanski, M., Troutman, C., Anderson, J., Johnson, G., McNulty, S. E., Clapp-Channing, N., Davidson-Ray, L. D., Fraulo, E. S., Fishbein, D. P., Luceri, R. M., Ip, J. H.: Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N. Engl. J. Med., 2005, 352: 225–237.
  45. Grimm, W., Christ, M., Bach, J., Müller, H., Maisch, B.: Noninvasive arrhythmia risk stratification in idiopathic dilated cardiomyopathy: results of the Marburg Cardiomyopathy Study. Circulation, 2003, 108: 2883–2891.
  46. Steinbeck, G., Andresen, D., Senges, J., Hoffmann, E., Seidl, K., Brachmann, J.: Immediate Risk-Stratification Improves Survival (IRIS): study protocol. Europace, 2004, 6: 392–399.
  47. The DAVID Trial Investigators. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator. J. Am. Med. Assoc., 2002, 288: 1–19.
  48. Sweeney, M. O., Ellenbogen, K. A., Casavant, D., Betzold, R., Sheldon, T., Tang, F., Mueller, M., Lingle, J.: Multicenter, prospective, randomized safety and efficacy study of a new atrial-based managed ventricular pacing mode (MVP) in dual chamber ICDs. J. Cardiovasc. Electrophysiol., 2005, 16: 811–817.
  49. Olshansky, B., Day, J. D., Moore, S., Gering, L., Rosenbaum, M., McGuire, M., Brown, S., Lerew, D. R.: Is dual-chamber programming inferior to single-chamber programming in an implantable cardioverter-defibrillator? Results of the INTRINSIC RV (Inhibition of Unnecessary RV Pacing With AVSH in ICDs) study. Circulation, 2007, 115: 9–16.
  50. Epstein, A. E., DiMarco, J. P., Ellenbogen, K. A. et al: ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation, 2008, 117: e350–408.
  51. Ferreira-González, I., Dos-Subirá, L., Guyatt, G. H.: Adjunctive antiarrhythmic drug therapy in patients with implantable cardioverter defibrillators: a systematic review. Eur. Heart J., 2007, 28: 469–477.
  52. Bagherzadeh, A., Emkanjoo, Z., Haghjoo, M., Farahani, M. M., Alizadeh, A., Sadr-Ameli, M. A.: Complications and mortality of single versus dual chamber implantable cardioverter defibrillators. Indian Pacing Electrophysiol. J., 2006, 6: 75–83.
  53. Alexander, M. E., Cecchin, F., Walsh, E, P., Triedman, J. K., Bevilacqua, L. M., Berul, C. I.: Implications of implantable cardioverter defibrillator therapy in congenital heart disease and pediatrics. J. Cardiovasc. Electrophysiol., 2004, 15: 72–76.
  54. Dorwarth, U., Frey, B., Dugas, M. et al.: Transvenous defibrillation leads: high incidence of failure during long-term follow-up. J. Cardiovasc. Electrophysiol., 2003, 14: 38–43.
  55. Theuns, D. A. M. J., Rivero-Ayerza, M., Boersma, E., Jordaens, L.: Prevention of inappropriate therapy in implantable defibrillators: A meta-analysis of clinical trials comparing single-chamber and dual-chamber arrhythmia discrimination algorithms. Int. J. Cardiol., 2008, 125: 352–357.
  56. Pinter, A., Dorian, P.: Approach to antiarrhythmic therapy in patients with ICDs and frequent activations. Curr. Cardiol. Rep., 2005, 7: 376–381.
  57. Stevenson, W. G., Chaitman, B. R., Ellenbogen, K. A. et al.: Clinical assessment and management of patients with implanted cardioverter-defibrillators presenting to nonelectrophysiologists. Circulation, 2004, 110: 3866–3869.
  58. Lee, M. A., Weachter, R., Pollak, S. et al.: The effect of atrial pacing therapies on atrial tachyarrhythmia burden and frequency: results of a randomized trial in patients with bradycardia and atrial tachyarrhythmias. J. Am. Coll. Cardiol., 2003, 41: 1926–1932.
  59. Whang, W., Albert, C. M., Sears, S. F. J. et. al.: Depression as a predictor for appropriate shocks among patients with implantable cardioverter-defibrillators: results from the Triggers of Ventricular Arrhythmias (TOVA) study. J. Am. Coll. Cardiol., 2005, 45: 1090–1095.
  60. Friedman, P. A., Jalalm S., Kaufmanm S. et al.: Effects of a rate smoothing algorithm for prevention of ventricular arrhythmias: results of the Ventricular Arrhythmia Suppression Trial (VAST). Heart Rhythm., 2006, 3: 573–580.
  61. Vardas, P. E., Auricchio, A., Blanc, J. et al.: Guidelines for cardiac pacing and cardiac resynchronization therapy: the task force for cardiac pacing and cardiac resynchronization therapy of the European Society of Cardiology. Developed in collaboration with the European Heart Rhythm Association. Eur. Heart J., 2007, 28: 2256–2295.
  62. Mushlin, A. I., Hall, W. J., Zwanziger, J. et al.: The cost-effectiveness of automatic implantable cardiac defibrillators: results from MADIT. Multicenter Automatic Defibrillator Implantation Trial. Circulation, 1998, 97: 2129–2135.
  63. Lynd, L. D., O’Brien, B. J.: Cost-effectiveness of the implantable cardioverter defibrillator: a review of current evidence. J. Cardiovasc. Electrophysiol., 2003, 14: S99–103.
  64. Owens, D. K., Sanders, G. D., Heidenreich, P. A., McDonald, K. M., Hlatky, M. A.: Effect of risk stratification on cost-effectiveness of the implantable cardioverter defibrillator. Am. Heart J., 2002, 144: 440–448.
  65. Sanders, G. D., Hlatky, M. A., Owens, D. K.: Cost-effectiveness of implantable cardioverter-defibrillators. N. Engl. J. Med., 2005, 353: 1471–1480.
Klinikai szív-elektrofiziológia és aritmológia

Tartalomjegyzék

Kiadó: Akadémiai Kiadó

Online megjelenés éve: 2016

ISBN: 978 963 059 748 7

Orvostudomány

A Klinikai szív-elektrofiziológia és aritmológia első kiadását a szívritmuszavarok patofiziológiájában, farmakológiájában, diagnosztikájában és gyógyításában kiemelkedően jártas hazai szakírók vetették papírra. Az aritmiában szenvedő betegek optimális ellátásához nélkülözhetetlen, az idő tájt rendelkezésre álló elméleti és klinikai tudnivalókat átfogóan ismertető kézikönyv iránti olvasói érdeklődés és a Magyar Tudományos Akadémia Orvosi Osztályának Nívódíja bizonyította, hogy a szerzők és a szerkesztők erőfeszítései nem voltak haszontalanok. Egy évtized az élettudományok fejlődésének jelenlegi tempóját figyelembe véve nagyon hosszú idő. Az elektrofiziológia és (a)ritmológia mind a mai napig a szívgyógyászat egyik legdinamikusabban fejlődő technicizálódó ága, melynek vertikuma egyre nagyobb: a szívizom szabályos ritmikáját megzavaró, nemritkán öröklődő patobiokémiai eltérések felismerésétől az új típusú, innovatív gyógyszerek hozzáértő alkalmazásán keresztül az egyre kifinomultabb invazív terápiás eljárásokig ível. Ennélfogva idő- és szükségszerűvé vált a lényegbevágóan új diagnosztikai / képalkotó módszerek, gyógyszeres és instrumentális kezelési módozatok, valamint a nagy mintaszámú, randomizált, kontrollcsoportos arrhythmiavizsgálatok eredményein nyugvó és a szakmai tudományos irányelvek főbb útmutatásait visszatükröző ismeretek friss, kézikönyvbe foglalt szintézise: a tudományág fejlődésével lépést tartó jelen, második, új fejezetek beépítésével és a régebbiek újraírásával, felülvizsgálatával gazdagított kiadás megírása, összeállítása.

Hivatkozás: https://mersz.hu/fazekas-merkely-papp-tenczer-klinikai-sziv-elektrofiziologia-es-aritmologia//

BibTeXEndNoteMendeleyZotero
Kivonat
fullscreenclose
printsave